Biotechnology is one of the most dynamic areas of the life sciences industry. Scientific excellence, regulatory requirements, capital market pressure and societal impact come together directly in this field. Whether cell and gene therapies, RNA-based platforms, personalised medicine or AI-enabled drug discovery – biotech companies need leaders who can successfully drive innovation from a strategic, regulatory and commercial perspective.
Switzerland is one of Europe’s leading biotech locations. Basel, Zurich/Zug/Schlieren, Lausanne, Geneva and the Health Valley of Western Switzerland bring together pharmaceutical companies, specialised biotech firms, universities, hospitals, CDMOs, investors and regulatory expertise within a highly concentrated ecosystem. This density creates opportunities, but also intensifies the competition for outstanding leadership talent.
Wirz & Partners supports biotech companies, life sciences investors and growth-oriented organisations in filling key positions at board, C-level and senior management level. We identify leaders who understand biotechnology from a technical perspective and can guide companies through critical development phases – from proof of concept, clinical trials and regulatory strategy to financing, partnerships, market entry or exit.
Biotech companies face a distinct leadership challenge: organisations are often highly specialised, internationally oriented and capital-intensive – while frequently still being in an early development or scaling phase. Leaders therefore need more than outstanding technical expertise. They must be able to navigate ambiguity, convince investors, build teams and steer regulatory milestones with precision.
Typical challenges in the biotech environment include:
Wirz & Partners identifies these requirements early and develops search profiles that go beyond traditional job descriptions. The decisive factor is not only whether someone has previously held a specific function, but whether the person fits the company’s development stage, financing situation, culture and strategic ambition.
The Swiss biotech sector continues to demonstrate strong resilience despite volatile capital markets. The market is shaped by high investments in research and development, financing from private equity, venture capital and institutional investors, international alliances and proximity to leading pharmaceutical and research institutions. At the same time, expectations placed on leadership teams are rising: investors demand clear milestones, regulators expect robust data, partners assess strategic fit and talent looks for organisations with a credible mission.
Switzerland benefits from several structural strengths:
Basel Area
Basel is one of the world’s most important pharma and biotech locations. Roche, Novartis, research institutions, incubators and specialised service providers create an environment where scientific innovation, clinical development and global scaling are closely connected.
Health Valley and Western Switzerland
Lausanne, Geneva, Bern and Valais form a dense life sciences ecosystem with EPFL, CHUV, Campus Biotech, Biopôle Lausanne, BioArk and other innovation platforms. The region is particularly strong in translational research, clinical collaborations, digital health, diagnostics and MedTech-related biotechnology.
Greater Zurich, Zug and Schlieren
Zurich and Zug combine international headquarters, investors, universities, hospitals and biotech start-ups. ETH Zurich, University Hospital Zurich, Bio-Technopark Schlieren and global life sciences companies such as Biogen, Amgen, BMS, AbbVie, Gilead and Alnylam shape the region’s ecosystem.
International alliances
Biotech is global by nature. Swiss companies rarely develop products, platforms and therapies in isolation, but in partnership with pharmaceutical companies, universities, hospitals, CDMOs, investors and regulatory stakeholders. Leaders therefore need to combine scientific depth with the ability to collaborate internationally.
Our experience shows that leadership requirements in biotech vary significantly depending on the company’s development stage. A preclinical platform company requires different profiles than a clinical Phase II company, a CDMO-related growth business or a listed biotech company with an international partnering focus.
Typical responsibilities and requirements include:
With our executive search approach, we identify leaders who not only master these responsibilities functionally, but also fit the company’s stage, culture and strategic direction.
In biotechnology, every key appointment is a strategic decision. A new CEO can change a company’s financing capability. An experienced CMO can sharpen the clinical development strategy. A strong CBO can open access to pharma partnerships. An independent board member can strengthen governance, investor confidence and scientific prioritisation.
Especially in early-stage and high-growth biotech companies, the talent market is often not transparent. The best leaders are rarely actively looking. They need to be identified selectively, approached discreetly and engaged with a compelling strategic narrative.
Wirz & Partners acts as a sparring partner for founders, boards, investors and executive teams. We understand the language of science, capital markets, regulation and corporate leadership – and translate this into a search profile that reflects the company’s true success factors.
Our goal is not simply to fill an open position quickly. Our goal is to find the right leader for the next stage of development.
We bring together scientific excellence, regulatory understanding and leadership perspective – with precision, discretion and a focus on long-term impact.
Whether CEO, CMO, CSO, CFO, CBO, Head of Clinical Development, Head of Regulatory Affairs or board member – we find leaders who can guide your biotech company into its next stage of development.